Our review highlights the status of exogenous lncRNA H19 as a potential diagnostic marker and therapeutic target in the development of cholestatic liver fibrosis, and the potential of targeting these intercellular signaling mechanisms and mediators to increase sensitivity and improve response to conventional therapeutic agents used to treat liver fibrosis and to complement exogenous lncRNAs strategies in liver prevention, diagnosis and treatment. This evidence concerns the gene H19 and Hepatic fibrosis.